Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC ; volume:19 ; number:2 ; day:11 ; month:3 ; year:2024 ; pages:131-134 ; date:3.2024
Targeted oncology ; 19, Heft 2 (11.3.2024), 131-134, 3.2024
- Urheber
-
Tsuboi, Masahiro
Herbst, Roy S.
John, Thomas
Kato, Terufumi
Majem, Margarita
Grohé, Christian
Wang, Jie
Goldman, Jonathan W.
Lu, Shun
Marinis, Filippo de
Shepherd, Frances A.
Lee, Ki Hyeong
Le, Nhieu Thi
Dechaphunkul, Arunee
Kowalski, Dariusz
Bonanno, Laura
Dómine, Manuel
Poole, Lynne
Bolanos, Ana
Rukazenkov, Yuri
Wu, Yi-Long
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-024-01034-3
- URN
-
urn:nbn:de:101:1-2405271059004.973279636325
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsuboi, Masahiro
- Herbst, Roy S.
- John, Thomas
- Kato, Terufumi
- Majem, Margarita
- Grohé, Christian
- Wang, Jie
- Goldman, Jonathan W.
- Lu, Shun
- Marinis, Filippo de
- Shepherd, Frances A.
- Lee, Ki Hyeong
- Le, Nhieu Thi
- Dechaphunkul, Arunee
- Kowalski, Dariusz
- Bonanno, Laura
- Dómine, Manuel
- Poole, Lynne
- Bolanos, Ana
- Rukazenkov, Yuri
- Wu, Yi-Long
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC